Focus On Asia
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
![](/-/media/editorial/scrip/2024/07/sc2407_anges_collategene_shutterstock_1378933043_1200.jpg?rev=65c8e39b25ab456291419aa52f3b6dfb&w=350&hash=48960E8A2BD61E67D480C1D5D62172DD)
AnGes To Withdraw, Refile HGF Gene Therapy In Japan
If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.
![](/-/media/editorial/scrip/2024/06/sc2406_parexelexecutives_1200.jpg?rev=90c4f7ad5cb84d0eb3b39a697d560d5b&w=350&hash=9D5E08446735DE96B14F1C91D707102E)
Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity
Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.
![](/-/media/editorial/scrip/2024/06/sc2305_china_obesity_1088402456_1200.jpg?rev=8e3b917a8ec444dab6395fc9ff4a2c96&w=350&hash=E0E4C0F6CCD44D245673D015A7F900F8)
ADA: Hengrui, Innovent’s Incretins Shine In China Obesity Studies
Positive clinical outcomes for Hengrui and Innovent/Lilly’s obesity candidates presented at ADA were based on trials that enrolled Chinese subjects and were characterized by fewer women and less severe obesity than similar Western studies. Even so, some of the data appear to stack up well against western rival drugs.
![](/-/media/editorial/scrip/00_regular-column-images/chinesebiotech_podcast_1200.jpg?rev=d3d2a7761a5b4b608755f8bc405705b6&w=350&hash=0937111524C56EFA47CE6E840881483D)
China Biotech Podcast: 数据出境新规解读,EHA和ADA的中国数据发布
In this Chinese-language podcast episode, "Angus" Shipo Xie, a lawyer at Han Kun Law, joins Brian Yang to discuss the implications of China's updated Data Overseas Transfer rules issued in late March. Dexter Yan explains clinical data released by Hutchmed, Jiangsu Hengrui and Innovent Bio at the recent EHA and ADA annual conferences.
![](/-/media/editorial/scrip/2024/06/sc2406_sanbio_shutterstock_2443807533_1200.jpg?rev=a576ade0402a4ad0b3523b340f2d6a75&w=350&hash=E47DA7327493C920914CF8648869FE1D)
Conditional Global-First Nod For SanBio's Cell Therapy for TBI
SanBio’s lead cell therapy asset has been on a bumpy journey to its global-first approval and while a nod has now come in Japan in a high-need indication, a commercial launch is conditional on additional data to establish product equivalence and manufacturing consistency.
![](/-/media/editorial/scrip/2024/06/ipa-citeline-new-cgt-image-1200x675.jpg?rev=aa9cceb53833451db864bb96d07f77a4&w=350&hash=F881FBF96A69FA072D4ADAD41E3D7EAE)
As India Scales CAR-T Efforts, Can It Innovate Commercial Models?
As India seeks to build on early gains in CAR-T cell therapy, experts call for ecosystem reform and also the need to demonstrate value to payer models of large economies to potentially back international reimbursements.
![](/-/media/editorial/scrip/2024/06/joerg-ahlgrimm-ceo-sk-pharmteco-at-bio-usa.jpg?rev=26aa1c8639f743bfb6e0506bd5fbe6a7&w=350&hash=0CF7CE7982402F946BB75C6832755766)
SK pharmteco Focusing On BAU Amid BIO 'Buzz', BIOSECURE
SK pharmteco CEO Joerg Ahlgrimm talks to Scrip about the "excitement" at BIO, potential CDMO shifts amid the US BIOSECURE Act, and the Korean CDMO's focus on business as usual as it seeks to diversify and grow.
![](/-/media/editorial/scrip/2023/07/sc2307_first_line_171888440_1200.jpg?rev=4f9084c1329a43bd8cadda0192f8b62a&w=350&hash=EDD9FF09392EE73275485DFBB173080A)
Dizal Scores First JAK1 Approval For Advanced PTCL
China's Dizal has won the first approval worldwide, in its home market, for a JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma (PTCL), based on a pivotal Phase II trial. The biotech is also planning a Phase III study with the molecule for second-line PTCL.
![](/-/media/editorial/scrip/2024/06/sc2406_stargardt_japan_shutterstock_2250351141_1200.jpg?rev=de1b3e72ea5147a78ba109a5dcdb5e80&w=350&hash=693C6FC6AD4E4994E958B70C41300268)
Multiple Stargardt Contenders Progress In Japan Despite Small Market
With no approved therapies globally for Stargardt's, competition in the indication is increasing in Japan, where Kubota Vision is seeking for conditional approval for emixustat, while Belite Bio’s contender tinlarebant has received Sakigake designation as a local Phase III program continues.
![](/-/media/editorial/scrip/2024/06/sc2406_parexelexecutives_1200.jpg?rev=90c4f7ad5cb84d0eb3b39a697d560d5b&w=350&hash=9D5E08446735DE96B14F1C91D707102E)
Parexel On Reimbursement Support, Federated Data Sharing, Diversity Through Communities
Parexel’s chief strategy officer, clinical EVP and India head share thoughts on a winner’s mindset for artificial intelligence, benefits of a “federated approach” to clinical data sharing, support for reimbursement and a cascading impact of obesity treatments, in a two-part interview with Scrip.
![](/-/media/editorial/scrip/2024/06/sc2406_succession_1855063867_1200.jpg?rev=8c503fe7f3f149009887d94e505e9ce9&w=350&hash=A18FF2DEA544FC988318F0DD3147663F)
Takeda Options Potential Iclusig Successor In Ascentage Deal
Takeda has signed an option deal for Ascentage's olverembatinib, being investigated in two global Phase III trials in the same leukemia indications as those for the Japanese firm's existing drug Iclusig. Olverembatinib has also shown potential to overcome resistance to Iclusig and global competitor Novartis's Scemblix.
![](/-/media/editorial/scrip/2024/06/sc2406_tohoku_japan_p2_shutterstock_595903445_1200.jpg?rev=3f4e403b9d5746dca93eda18e35019a5&w=350&hash=75061CBEEA2C577C90409B60CB836180)
Japan Academia Progresses Novel Melanoma Drug Despite Pharma 'Reluctance'
Academia-developed novel oral PAI-1 inhibitor in combination with Opdivo showed a strong response rate in PD-1 treated melanoma patients with certain disease characteristics and could represent a new breakthrough for a class with no clinical stage competitors.
![](/-/media/editorial/scrip/2024/06/sc2406_blood_2248148893_1200.jpg?rev=9b0c3f89542742348ab11121e31516ce&w=350&hash=D7C324655B9235DB543F5B5F5CD9C130)
China Phase III Results Boost Global Prospects For HUTCHMED ITP Drug
The Phase III ESLIM-01 study with HUTCHMED’s Syk inhibitor sovleplenib met its primary endpoint, demonstrating a 48.4% durable response rate for chronic immune thrombocytopenia, significantly higher than placebo. Global development appears to be accelerating and a multinational dose-finding Phase Ib study has also been initiated.
![](/-/media/editorial/scrip/00_regular-column-images/sc2107_asia_deal_watch_c04t5x_1200.jpg?rev=bd074a70fcbd4cf3b769a18a4317a807&w=350&hash=2DEFCFF2790EC02CDFB1AAB9286095A3)
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
![](/-/media/editorial/scrip/2024/06/sun-north-america-ceo-abhay-gandhi-1200x675.jpg?rev=7fdbe8525ff6405d898e6ce4605e0f59&w=350&hash=CE5257454E966DDF5EA2D7615650D887)
Sun’s Gandhi On US Specialty Journey Sans ‘Baggage’, Deuruxolitinib
Sun’s CEO (North America) Abhay Gandhi tells Scrip how not many gave the firm a chance in the US with Ilumya, now with global sales of over half a billion dollars, and outlines prospects of deuruxolitinib for alopecia areata. India’s top-ranked drug maker also has an eye on China R&D assets.
![](/-/media/editorial/scrip/2024/06/sc2406_ovarian_2161724253_1200.jpg?rev=5f198007946d446481cb7e125f126173&w=350&hash=8C42D4A5C498946296D5BD73DA524ED3)
ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer
In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.